Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jul 20:3:215.
doi: 10.3389/fimmu.2012.00215. eCollection 2012.

Cross-reactive broadly neutralizing antibodies: timing is everything

Zelda Euler  1 , Hanneke Schuitemaker
Affiliations

Cross-reactive broadly neutralizing antibodies: timing is everything

Zelda Euler et al. Front Immunol. .

Abstract

The recent surge of research into new broadly neutralizing antibodies in HIV-1 infection has recharged the field of HIV-1 vaccinology. In this review we discuss the currently known broadly neutralizing antibodies and focus on factors that may shape these antibodies in natural infection. We further discuss the role of these antibodies in the clinical course of the infection and consider immunological obstacles in inducing broadly neutralizing antibodies with a vaccine.

Keywords: HIV-1; HIV-1 disease progression; broadly neutralizing antibodies; cross-reactive broadly neutralizing antibodies; humoral immunity.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Sequentially elicited antibodies to HIV-1 envelope over the course of the infection.
FIGURE 2
FIGURE 2
Epitope specificity of known broadly neutralizing antibodies to HIV-1 envelope. Adapted from White et al. (2010).
See this image and copyright information in PMC

References

    1. Abdool K. Q., Abdool Karim S. S., Frohlich J. A., Grobler A. C., Baxter C., Mansoor L. E., Kharsany A. B., Sibeko S., Mlisana K. P., Omar Z., Gengiah T. N., Maarschalk S., Arulappan N., Mlotshwa M., Morris L., Taylor D. (2010). Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329 1168–1174 - PMC - PubMed
    1. Alam S. M., McAdams M., Boren D., Rak M., Scearce R. M., Gao F., Camacho Z. T., Gewirth D., Kelsoe G., Chen P., Haynes B. F. (2007). The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J. Immunol. 178 4424–4435 - PMC - PubMed
    1. Alam S. M., Morelli M., Dennison S. M., Liao H. X., Zhang R., Xia S. M., Rits-Volloch S., Sun L., Harrison S. C., Haynes B. F., Chen B. (2009). Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc. Natl. Acad. Sci. U.S.A. 106 20234–20239 - PMC - PubMed
    1. Amanna I. J., Messaoudi I., Slifka M. K. (2008). Protective immunity following vaccination: how is it defined? Hum. Vaccin. 4 316–319 - PMC - PubMed
    1. Auvert B., Taljaard D., Lagarde E., Sobngwi-Tambekou J., Sitta R., Puren A. (2005). Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2 e298 10.1371/journal.pmed.0020298 - DOI - PMC - PubMed

LinkOut - more resources